Evidence map›Paper›PMID 41013341›Full record

ArticleBMC gastroenterology2025

Identification of a dihydroartemisinin-related prognostic signature and its contribution to cancer associated fibroblast of the tumor microenvironment of pancreatic cancer.

Jinglin Lai, Tongning Zhong, Citing Zhang, Chongzhou Fang, Defeng Lei, Yong Xie, Xu Liu, Zhengquan Lai, Zilong Yan, Weipeng Ai and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Therapeutic Potential of Dihydroartemisinin in Cancer Treatment.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jinglin Lai *Central Laboratory, Peking University Shenzhen Hospital, Shenzhen, 518000, Guangdong, China.
Tongning Zhong *Central Laboratory, Peking University Shenzhen Hospital, Shenzhen, 518000, Guangdong, China.
Citing Zhang *Department of Pharmacy, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University, Shenzhen, 518000, Guangdong, China.
Chongzhou FangCentral Laboratory, Peking University Shenzhen Hospital, Shenzhen, 518000, Guangdong, China.
Defeng LeiDepartment of Hepatobiliary Surgery, Peking University Shenzhen Hospital, Shenzhen, 518000, Guangdong, China.
Yong XieDepartment of Hepatobiliary Surgery, Peking University Shenzhen Hospital, Shenzhen, 518000, Guangdong, China.
Xu LiuDepartment of Hepatobiliary Surgery, Peking University Shenzhen Hospital, Shenzhen, 518000, Guangdong, China. liuxu_pkuszh@163.com.
Zhengquan LaiDepartment of Pharmacy, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University, Shenzhen, 518000, Guangdong, China. cruise0303@163.com.
Zilong YanDepartment of Hepatobiliary Surgery, Peking University Shenzhen Hospital, Shenzhen, 518000, Guangdong, China. 380785219@qq.com.
Weipeng AiDepartment of Pharmacy, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University, Shenzhen, 518000, Guangdong, China. 476139238@qq.com.
Jianhua QuDepartment of Hepatobiliary Surgery, Peking University Shenzhen Hospital, Shenzhen, 518000, Guangdong, China. qjh@jianhua.info.
Biao ZhengDepartment of Surgery, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523710, Guangdong, China. zhengbiao@gdmu.edu.cn.

Funding

Guangdong Basic and Applied Basic Research Foundation 2021A1515110526Guangdong Basic and Applied Basic Research Foundation 2023A1515011950Shenzhen Science and Technology Program JCYJ20220531094215034Talent Development Foundation of The First Dongguan Affiliated Hospital of Guangdong Medical University GCC2023019the National Natural Science Foundation of China 82174137the National Natural Science Foundation of China 82303436The Science and Technology Planning Project of Shenzhen City JCYJ20220531103010022
6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) is characterized by high metastatic potential and a stroma-rich tumor microenvironment (TME). Dihydroartemisinin (DHA) has shown antitumor potential in various cancers, but its therapeutic effects on the TME of PDAC are not yet understood.

methodsDHA-related differentially expressed genes (DEGs) were identified by high-throughput RNA sequencing in PDAC cells and utilized to explore the biological functions of DHA. The clinical value of DHA was examined by constructing a prognostic risk model using the TCGA dataset. We identified SERPINB5 as a downstream target of DHA involved in TME remodeling through cancer-associated fibroblast (CAF) regulation. The clinical value of SERPINB5 was validated through prognostic risk modeling and immunohistochemistry staining.

resultsOur findings indicate that DHA may affect CAF-mediated TME remodeling. Prognostic risk modeling indicates that DHA was associated with PDAC prognosis, implying its clinical potential. DHA may improve the prognosis of PDAC patients by downregulating the expression of SERPINB5, which may participate in regulating CAFs.

conclusionsThis study suggests that DHA might improve the prognosis of PDAC patients, and it may influence the PDAC TME by downregulating SERPINB5, offering new insights into DHA’s antitumor mechanisms and its potential clinical applications in PDAC treatment.

Indexed as

Antineoplastic AgentsArtemisininsCancer-Associated FibroblastsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsTumor MicroenvironmentCell Line, TumorDown-RegulationFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisSerpinsAntineoplastic AgentsArtemisininsartenimolSERPIN-B5SerpinsDihydroartemisininPancreatic ductal adenocarcinomaSERPINB5Tumor microenvironment

Identifiers

PMID41013341
PMCPMC12465723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.